Article Figures & Tables
Figures
- Fig. 1.
Muscle characteristics in different muscular dystrophy mouse models. (A) H&E-stained section of tibialis anterior from a 3-week-old: (i) WT mouse showing normal, regular myofibres with peripheral nuclei and intact sarcoplasm; and (ii) mdx, (iii) mdx:Utrn+/− (shown as mdx:utr in the figure) and (iv) mdx:Cmah−/− mouse, showing many inflammatory cells with a barely visible sarcoplasm. (B) H&E-stained section of tibialis anterior from a 7-week-old: (i) WT mouse showing normal, regular myofibres with peripheral nuclei and intact sarcoplasm; and (ii) mdx, (iii) mdx:Utrn+/− and (iv) mdx:Cmah−/− mouse, showing regeneration with larger myofibres and central nuclei. (C) Muscle cell inflammation was present in all muscular dystrophy models by 3 weeks of age followed by regeneration at 5 and 7 weeks of age. (D) Mean grip strength by age and genotype, showing a reduction in muscular dystrophy mice. (E) Higher CK activity in muscular dystrophy mice at all ages. Data are presented as mean±s.d. (n>6); *P<0.05, **P<0.01, ***P<0.001 for cumulative measures of muscle damage compared to WT mice. (F) Increased weight gain is seen in the young mdx:Cmah−/− mice. (Fi) Increased rate of weight gain in the mdx:Cmah−/− mice occurred between 3 and 5 weeks of age but not between 5 and 7 weeks of age. Data presented are mean (symbol) and standard deviation (whiskers). *P<0.05 compared to WT mice. (Fii) Example of a growth chart for a WT mouse compared to an mdx:Cmah−/− mouse, showing the lower initial weight and the rapid growth velocity seen in the early weeks in the mdx:Cmah−/− mouse.
- Fig. 2.
Longitudinal bone growth rate in muscular dystrophy mouse models. (A) Longitudinal bone growth during the study period. Data are presented as mean±s.d. *P<0.05 compared to WT mice of the same age. (B) Examples of calcein-labelled GP in a 5-week-old (i) mdx:Cmah−/− and (ii) mdx mouse, showing the increased longitudinal growth rate in the mdx:Cmah−/− mouse (red arrows).
- Fig. 3.
Bone parameters in muscular dystrophy mouse models. (A) Representative µCT images of tibial bone of all genotypes at 3, 5 and 7 weeks of age to show bone development (upper row, mid diaphyseal cortical bone; lower row, metaphyseal trabecular bone). (B) Compared to similarly aged WT mice, cortical bone fraction was lower in mdx:Cmah−/− mice at 3 weeks of age, but higher in all muscular dystrophy models at 7 weeks of age. (C) Cortical tissue mineral density was higher in mdx:Cmah−/− mice at 3 and 7 weeks of age and in mdx:Utrn+/− (shown as mdx:utr in the figure) mice at 5 weeks when compared to WT mice. (D) Trabecular tissue volume was lower in mdx:Cmah−/− mice at 3 and 7 weeks of age compared with WT. (E) Trabecular connectivity was lower in mdx:Utrn+/− mice at 5 weeks and mdx:Cmah−/− mice at both 5 and 7 weeks when compared to WT mice. (F,G) The number of osteoblasts (F; N.Ob/BS) and osteoclasts (G; N.Oc/BS) per bone surface were normal in all muscular dystrophy models at 5 weeks of age. Data are presented are mean±s.d. (n>6); *P<0.05, **P<0.01, ***P<0.001 compared to WT mice.
- Fig. 4.
IGF-1 immunohistochemistry in muscular dystrophy mouse models. Immunolocalisation of IGF-1 in sections of (A) WT and (B) mdx:Cmah−/− tibiae, showing greater staining intensity in cells of both ossification centres and the growth plate (GP). (C) Control section in which rabbit IgG was substituted for the primary antibody. (D) Quantification of IGF-1 staining in GP chondrocytes and metaphysis of tibiae from WT and muscular dystrophy mouse models. Data are presented as mean±s.d. (n=6). *P<0.05, **P<0.01 compared to WT mice.
- Fig. 5.
Bone marrow adiposity in muscular dystrophy mouse models. Three-dimensional µCT reconstructions of 7-week-old osmium-stained tibiae from: (A) WT, (B) mdx and (C) mdx:Cmah−/− mice. Bone appears grey and BMAT is white. (D) The boundaries of rBMAT and cBMAT within the tibia are shown; rBMAT lies proximal to tibia/fibula junction and cBMAT lies distal to tibia/fibula junction (shown by dashed line). (E-G) Percentage of (E) total BMAT, (F) rBMAT, (G) cBMAT. Data are presented as mean±s.d. (n=5). *P<0.05, **P<0.01 compared to WT mice. Ad.V/Ma.V, adipose volume/marrow volume.
Article navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Subject collections
Other journals from The Company of Biologists
DMM and COVID-19
We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.
Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.
Professor Elizabeth Patton appointed as DMM’s next Editor-in-Chief
We are pleased to announce that The Company of Biologists directors have appointed Professor Elizabeth Patton as DMM's new Editor-in-Chief. As Paresh Vyas writes in his Editorial, Liz ‘brings vitality and a passion for the remit of DMM, and is deeply embedded in the community.’
Did you know DMM Conference Travel Grants can be used for online meetings?
With travel restrictions still in place, we want to continue supporting early-career researchers in their careers. DMM’s Conference Travel Grants can now be used to attend virtual and online scientific meetings, workshops, conferences and training courses.
The current application round closes on 8 February 2021 – find out more.
Identification of MYOM2 as a candidate gene in hypertrophic cardiomyopathy and Tetralogy of Fallot, and its functional evaluation in the Drosophila heart
Research from Silke Sperling and colleagues uses Drosophila to identify MYOM2 as a candidate gene in congenital heart malformations in this issue’s Editor’s choice.
C. elegans as a disease model
A new Research article from Doyle et al., models spinal muscular atrophy in C. elegans to show that that targeting therapies to muscle cells is more effective than neuronal delivery. Find more research using C. elegans as a disease model in our latest subject collection.
Call for papers – The RAS Pathway: Diseases, Therapeutics and Beyond
Our upcoming special issue is now welcoming submissions until 1 April 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on the targeting the RAS pathway. Find out more about the issue and how to submit your manuscript.
Interview – Kim Landry-Truchon and Nicolas Houde
In an interview, first authors Kim Landry-Truchon and Nicolas Houde discuss their mouse model of the early stages of pleuropulmonary blastoma, reflecting on the implications of their work and the future of their field.